Enzon Pharmaceuticals Inc (ENZN) financial statements (2021 and earlier)

Company profile

Business Address 20 COMMERCE DRIVE, SUITE 135
CRANFORD, NJ 07016
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4857781235
Cash and cash equivalents4857781235
Receivables 014   
Deferred tax assets    77
Other current assets0000000
Other undisclosed current assets0 7(4)   
Total current assets:486158812112
Noncurrent Assets
Nontrade receivables 012   
Deferred tax assets, net  311 
Total noncurrent assets: 012311 
Other undisclosed assets      (77)
TOTAL ASSETS:4861610112335
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities0010105
Accounts payable0000100
Accrued liabilities0000000
Employee-related liabilities      0
Interest and dividends payable      4
Other undisclosed current liabilities     5(0)
Total current liabilities:0010155
Noncurrent Liabilities
Liabilities, other than long-term debt      0
Accounts payable and accrued liabilities      0
Total noncurrent liabilities:      0
Total liabilities:0010155
Stockholders' equity
Stockholders' equity attributable to parent76159101830
Common stock1000000
Additional paid in capital787684849097130
Accumulated deficit(71)(70)(69)(75)(80)(79)(101)
Total stockholders' equity:76159101830
Other undisclosed liabilities and equity40      
TOTAL LIABILITIES AND EQUITY:4861610112335

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net881731
Gross profit:007881731
Operating expenses(1)(1)(1)(1)(2)(7)(2)
Operating income (loss):(1)(1)6771129
Nonoperating income
(Other Nonoperating income)
0     0
Income (loss) from continuing operations before income taxes:(1)(1)6771129
Income tax expense (benefit)(0)(0)(0)(2)(8)11(0)
Net income (loss) attributable to parent:(1)(1)65(1)2229
Preferred stock dividends and other adjustments(0)      
Net income (loss) available to common stockholders, diluted:(2)(1)65(1)2229

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(1)(1)65(1)2229
Comprehensive income (loss), net of tax, attributable to parent:(1)(1)65(1)2229

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: